Cough, Cold and Allergy (Hay Fever) Remedies in Brazil
In 2023, cough, cold and allergy (hay fever) remedies is set to maintain dynamic current value growth in Brazil. In this year, the conclusion of the Public Health Emergency of International Concern (PHEIC) for COVID-19, as declared by the World Health Organization (WHO), marked a significant turning point. Despite the waning demand for cough, cold, and allergy (hay fever) remedies in Brazil directly linked to COVID-19 cases, a new dynamic has emerged, propelling substantial current value growth.
Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Brazil report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2019-2023, allowing you to identify the sectors driving growth. Forecasts to 2028 illustrate how the market is set to change.
Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report? * Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market’s major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop.
Cough, Cold and Allergy (Hay Fever) Remedies in Brazil
Euromonitor International
March 2024
List Of Contents And Tables
COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN BRAZIL
KEY DATA FINDINGS
2023 DEVELOPMENTS
Search for convenience and a good night’s sleep drive growth for decongestants and combination products
Increase in rhinovirus cases drives sales of paediatric cough, cold and allergy remedies, while competition increases for pharyngeal preparations
EMS SA expands its production capacity, Eurofarma completes purchase of Valda, and CIMED invests in diversification
PROSPECTS AND OPPORTUNITIES
Climate change likely to continue, and intensify cases of allergies in the forecast period
Inefficacy of phenylephrine declared by the FDA could negatively impact sales of decongestants in Brazil
Innovation through sustainable packaging and conscious disposal emerges as a differentiation strategy in a mature category
CATEGORY DATA
Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2018-2023
Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2018-2023
Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2023
Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2020-2023
Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2023-2028
Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2023-2028
CONSUMER HEALTH IN BRAZIL
EXECUTIVE SUMMARY
Consumer health in 2023: The big picture
2023 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2018-2023
Table 8 Life Expectancy at Birth 2018-2023
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2018-2023
Table 10 Sales of Consumer Health by Category: % Value Growth 2018-2023
Table 11 NBO Company Shares of Consumer Health: % Value 2019-2023
Table 12 LBN Brand Shares of Consumer Health: % Value 2020-2023
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2018-2023
Table 14 Distribution of Consumer Health by Format: % Value 2018-2023
Table 15 Distribution of Consumer Health by Format and Category: % Value 2023
Table 16 Forecast Sales of Consumer Health by Category: Value 2023-2028
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2023-2028
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification